BioCryst Pharmaceuticals (BCRX) Shares are Up 17.53%

BioCryst Pharmaceuticals (BCRX) : Traders are bullish on BioCryst Pharmaceuticals (BCRX) as it has outperformed the S&P 500 by a wide margin of 19.13% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 17.61%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.53% in the last 1 week, and is up 23.13% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 19.67% and the 50-Day Moving Average is 16.14%. BioCryst Pharmaceuticals, Inc. is up 11.04% in the last 3-month period. Year-to-Date the stock performance stands at -64.92%.


BioCryst Pharmaceuticals (NASDAQ:BCRX): stock turned positive on Friday. Though the stock opened at $3.47, the bulls momentum made the stock top out at $3.635 level for the day. The stock recorded a low of $3.4 and closed the trading day at $3.62, in the green by 4.62%. The total traded volume for the day was 906,637. The stock had closed at $3.46 in the previous days trading.

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.